Artemis - Breast Cancer Newsletter



	9-Country Study Shows Wide Variations in How Women with Early Breast Cancer are Treated Adolescent Drinking Adds to Risk of Benign Breast Disease, Breast Cancer Breast Cancer Patients with BRCA Mutations are Four Times More Likely to Get Cancer in Opposite Breast Breast Cancer Risk Factors Differ Among Races Cell Study Finds Receptor Can Fight Tamoxifen-Resistant Breast Cancer Cells Childhood Body Size May Be Linked to Future Breast Cancer Risk Clues to Pregnancy-Associated Breast Cancer Found Co-Administered Peptide Directs Medicines Deep Into Tumor Tissue, Increasing Drug Efficacy and Reducing Side Effects Comparison of Available Breast Cancer Risk Assessment Tools Shows Room for Improvement Decoding Tumor Genomes Reveals Clues to Spread of Deadly Breast Cancer Disparities Persist in Outcomes for African-American Women with Advanced Breast Cancer Early, Lifelong Surveillance for Breast Cancer Recommended for Young Women Treated with Chest Radiation Hormone Sensitivity of Breast Stem Cells Presents Drug Target How Breast Cancer Cells Evade Therapeutic Attacks Loss of the Breast Cancer Gene BRCA1 in the Absence of Genetic Mutations is Controlled by the Protein HOXA9 Radiation after Mastectomy Underused, Study Finds Researchers Show Potential for New Cancer Detection and Therapy Method Study Shows that Mutations in One Gene Cause Many Cancers Subtle Changes in PTEN Tumor Suppressor Gene Can Determine Cancer Susceptibility

Discovery that PARP Protein Exists in All Breast Tumors Will Help Target Chemo and Predict ResponseBreakthrough Method Predicts Risk of DCIS Becoming Invasive Breast Cancer

For the first time, scientists have discovered a way to predict whether women with ductal carcinoma in situ (DCIS) – the most common form of non-invasive breast cancer – are at risk of developing more invasive tumors in later years.

As a result of the finding, women with DCIS will have the opportunity to be more selective about their treatment, according to the scientists.

"Women will have much more information, so they can better know their risk of developing invasive cancer,'' said lead author Karla Kerlikowske, MD. "It will lead to a more personalized approach to treatment. As many as 44 percent of patients with DCIS may not require any further treatment, and can rely instead on surveillance.''

Avon Breast Cancer Crusade - AVON the company for women

This website is supported in part by an unrestricted educational grant provided by Avon